SCM
KRYS icon

Silvant Capital Management’s Krystal Biotech KRYS Stock Holding History

Silvant Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.7K Buy
+80
New +$23.9K ﹤0.01% 337

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Silvant Capital Management's KRYS Position: Q2 2026 in Review

Silvant Capital Management opened a new position in Krystal Biotech (KRYS) in Q2 2026: 80 shares worth $29.7K. The stake represents ﹤0.01% of the portfolio and ranks #337 among its holdings.

422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Silvant Capital Management held 80 shares of Krystal Biotech worth $29.7K as of Q2 2026.
  • Krystal Biotech was a new Silvant Capital Management position in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Silvant Capital Management's portfolio in Q2 2026, its #337 holding.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Silvant Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.